TSE:ONC - Oncolytics Biotech Stock Price, Price Target & More

C$0.70 0.00 (0.00 %)
(As of 04/22/2018 02:02 PM ET)
Previous CloseC$0.70
Today's RangeC$0.70 - C$0.74
52-Week RangeC$0.42 - C$1.12
Volume54,200 shs
Average Volume286,314 shs
Market CapitalizationC$111.15 million
P/E RatioN/A
Dividend YieldN/A
Beta1.04

About Oncolytics Biotech (TSE:ONC)

Oncolytics Biotech Inc., a development stage biopharmaceutical company, focuses on the discovery and development of pharmaceutical products for the treatment of cancer. The company is developing REOLYSIN, an immuno-oncology viral-agent that comprises three programs: chemotherapy combinations to trigger selective tumor lysis; immune modulator combinations to facilitate innate immune responses; and immuno-therapy combinations to produce adaptive immune responses. Oncolytics Biotech Inc. was founded in 1998 and is headquartered in Calgary, Canada.

Receive ONC News and Ratings via Email

Sign-up to receive the latest news and ratings for ONC and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry N/A
Sub-IndustryN/A
SectorN/A
SymbolTSE:ONC
CUSIPN/A
Phone+1-403-6707380

Debt

Debt-to-Equity RatioN/A
Current RatioN/A
Quick RatioN/A

Price-To-Earnings

Trailing P/E RatioN/A
Forward P/E RatioN/A
P/E GrowthN/A

Sales & Book Value

Annual SalesN/A
Price / SalesN/A
Cash FlowN/A
Price / CashN/A
Book ValueN/A
Price / BookN/A

Profitability

EPS (Most Recent Fiscal Year)N/A
Net IncomeN/A
Net MarginsN/A
Return on Equity-91.52%
Return on Assets-74.32%

Miscellaneous

EmployeesN/A
Outstanding Shares142,325,000

How to Become a New Pot Stock Millionaire

Oncolytics Biotech (TSE:ONC) Frequently Asked Questions

What is Oncolytics Biotech's stock symbol?

Oncolytics Biotech trades on the Toronto Stock Exchange (TSX) under the ticker symbol "ONC."

How were Oncolytics Biotech's earnings last quarter?

Oncolytics Biotech (TSE:ONC) released its earnings results on Friday, March, 9th. The company reported ($0.03) earnings per share (EPS) for the quarter. View Oncolytics Biotech's Earnings History.

When is Oncolytics Biotech's next earnings date?

Oncolytics Biotech is scheduled to release their next quarterly earnings announcement on Friday, May, 4th 2018. View Earnings Estimates for Oncolytics Biotech.

What price target have analysts set for ONC?

1 brokers have issued 1-year price targets for Oncolytics Biotech's shares. Their predictions range from C$3.25 to C$3.25. On average, they expect Oncolytics Biotech's share price to reach C$3.25 in the next year. View Analyst Ratings for Oncolytics Biotech.

Who are some of Oncolytics Biotech's key competitors?

Who are Oncolytics Biotech's key executives?

Oncolytics Biotech's management team includes the folowing people:
  • Dr. Matthew C. Coffey, Pres, CEO & Director
  • Mr. Kirk J. Look CA, Chief Financial Officer
  • Dr. Andres A. Gutierrez M.D., Ph.D., Chief Medical Officer (Age 57)
  • Mr. Michael Moore, VP of Investor Relations & Corp. Communications
  • Mr. Andrew R. de Guttadauro, Global Head of Bus. Devel. & Pres of Oncolytics Biotech (U.S.) Inc (Age 51)

Has Oncolytics Biotech been receiving favorable news coverage?

Media coverage about ONC stock has been trending somewhat positive recently, according to Accern. The research group ranks the sentiment of media coverage by monitoring more than 20 million news and blog sources in real time. Accern ranks coverage of public companies on a scale of negative one to one, with scores closest to one being the most favorable. Oncolytics Biotech earned a daily sentiment score of 0.17 on Accern's scale. They also gave media stories about the company an impact score of 46.17 out of 100, meaning that recent media coverage is somewhat unlikely to have an impact on the company's share price in the immediate future.

How do I buy shares of Oncolytics Biotech?

Shares of ONC and other Canadian stocks can be purchased through online brokerage accounts that support trading on the Toronto Stock Exchange (TSX). Brokers that permit trading on the TSX include Fidelity, Interactive Brokers, PennTrade and Charles Schwab.

What is Oncolytics Biotech's stock price today?

One share of ONC stock can currently be purchased for approximately C$0.70.

How big of a company is Oncolytics Biotech?

Oncolytics Biotech has a market capitalization of C$111.15 million.

How can I contact Oncolytics Biotech?

Oncolytics Biotech's mailing address is 1167 Kensington Cres Nw Suite 210 Calgary Alberta Canada T2n 1X7, CALGARY, AB 00000, Canada. The company can be reached via phone at +1-403-6707380.


MarketBeat Community Rating for Oncolytics Biotech (ONC)

Community Ranking:  3.1 out of 5 (star star star)
Outperform Votes:  100 (Vote Outperform)
Underperform Votes:  59 (Vote Underperform)
Total Votes:  159
MarketBeat's community ratings are surveys of what our community members think about Oncolytics Biotech and other stocks. Vote "Outperform" if you believe ONC will outperform the S&P 500 over the long term. Vote "Underperform" if you believe ONC will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Oncolytics Biotech (TSE:ONC) Price Target and Consensus Rating

  (How are Consensus Ratings Calculated?)
1 Wall Street analysts have issued ratings and price targets for Oncolytics Biotech in the last 12 months. Their average twelve-month price target is C$3.25, suggesting that the stock has a possible upside of 364.29%. The high price target for ONC is C$3.25 and the low price target for ONC is C$3.25. There are currently 1 hold rating for the stock, resulting in a consensus rating of "Hold."
Today30 Days Ago90 Days Ago180 Days Ago
Consensus Rating: HoldBuyBuyBuy
Consensus Rating Score: 2.002.673.003.00
Ratings Breakdown: 0 Sell Rating(s)
1 Hold Rating(s)
0 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
1 Hold Rating(s)
2 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
0 Hold Rating(s)
2 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
0 Hold Rating(s)
2 Buy Rating(s)
0 Strong Buy Rating(s)
Consensus Price Target: C$3.25C$2.08C$1.50C$1.50
Price Target Upside: 364.29% upside206.37% upside50.00% upside50.00% upside

Oncolytics Biotech (TSE:ONC) Consensus Price Target History

Price Target History for Oncolytics Biotech (TSE:ONC)

Oncolytics Biotech (TSE:ONC) Analyst Ratings History

Show:
DateBrokerageActionRatingPrice TargetDetails
2/26/2018Paradigm CapitalBoost Price TargetSpeculative BuyC$2.50 -> C$3.25View Rating Details
4/13/2017BMO Capital MarketsBoost Price TargetOutperformC$1.00 -> C$1.50View Rating Details
4/13/2017Royal Bank of CanadaBoost Price TargetOutperformC$1.00 -> C$1.50View Rating Details
(Data available from 4/22/2016 forward)

Earnings

Oncolytics Biotech (TSE:ONC) Earnings History and Estimates Chart

Earnings by Quarter for Oncolytics Biotech (TSE:ONC)

Oncolytics Biotech (TSE ONC) Earnings History by Quarter

DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
5/4/2018        
3/9/2018Q4 2017C($0.03)ViewN/AView Earnings Details
11/8/2017Q3 2017C($0.03)C($0.02)ViewN/AView Earnings Details
8/3/2017Q2 2017C($0.03)C($0.03)ViewN/AView Earnings Details
5/5/2017Q1 2017C($0.03)C($0.03)ViewN/AView Earnings Details
3/10/2017Q4 2016C($0.04)ViewN/AView Earnings Details
11/3/2016Q3 2016C($0.03)ViewN/AView Earnings Details
8/4/2016Q2 2016C($0.02)ViewN/AView Earnings Details
5/6/2016Q1 2016C($0.03)ViewN/AView Earnings Details
3/11/2016Q4 2015C($0.03)ViewN/AView Earnings Details
11/5/2015Q3 2015C($0.02)ViewN/AView Earnings Details
8/6/2015Q2 2015C($0.03)ViewN/AView Earnings Details
5/7/2015Q1 2015C($0.04)ViewN/AView Earnings Details
3/13/2015Q4 2014C($0.04)ViewN/AView Earnings Details
11/6/2014Q3 2014C($0.05)ViewN/AView Earnings Details
8/7/2014Q2 14C($0.07)C($0.05)ViewN/AView Earnings Details
5/8/2014Q1 2014C($0.06)ViewN/AView Earnings Details
3/13/2014Q4 2013C($0.07)ViewN/AView Earnings Details
11/7/2013Q3 13C($0.07)C($0.07)ViewN/AView Earnings Details
8/1/2013Q2 2013C($0.06)ViewN/AView Earnings Details
5/9/2013Q1 2013C($0.11)C($0.08)ViewN/AView Earnings Details
3/14/2013Q4 2012C($0.10)C($0.11)ViewN/AView Earnings Details
11/8/2012Q3 2012C($0.13)C($0.12)ViewN/AView Earnings Details
8/2/2012Q2 2012C($0.12)C($0.13)ViewN/AView Earnings Details
5/10/2012Q1 2012C($0.10)C($0.11)ViewN/AView Earnings Details
3/15/2012Q4 2011C($0.10)C($0.16)ViewN/AView Earnings Details
11/10/2011Q3 2011C($0.07)C($0.09)ViewN/AView Earnings Details
7/28/2011Q2 2011C($0.07)C($0.09)ViewN/AView Earnings Details
5/12/2011Q1 2011C($0.07)C($0.06)ViewN/AView Earnings Details
3/17/2011Q4 2010C($0.06)C($0.12)ViewN/AView Earnings Details
11/10/2010Q3 2010C($0.08)C($0.07)ViewN/AView Earnings Details
7/29/2010Q2 2010C($0.07)C($0.07)ViewN/AView Earnings Details
5/12/2010Q1 2010C($0.08)C$0.07ViewN/AView Earnings Details
11/5/2009Q3 2009C($0.09)C($0.05)ViewN/AView Earnings Details
7/29/2009Q2 2009C($0.09)C($0.09)ViewN/AView Earnings Details
5/5/2009Q1 2009C($0.11)C($0.09)ViewN/AView Earnings Details
11/4/2008Q3 2008C$0.10ViewN/AView Earnings Details
7/29/2008Q2 2008C($0.13)ViewN/AView Earnings Details
4/30/2008Q1 2008C($0.08)ViewN/AView Earnings Details
(Earnings results data provided by Zacks Investment Research)

Dividends

Oncolytics Biotech (TSE:ONC) Dividend History by Quarter

AnnouncedPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
(Data available from 1/1/2013 forward)

Insider Trades

Oncolytics Biotech (TSE ONC) Insider Trading and Institutional Ownership History

Insider Trading History for Oncolytics Biotech (TSE:ONC)

Oncolytics Biotech (TSE ONC) Insider Trading History

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
5/26/2015Angela Frances HolthamDirectorBuy5,000C$0.89C$4,450.00
5/12/2015Wayne PisanoDirectorBuy20,000C$0.76C$15,150.00
(Data available from 1/1/2013 forward)

Headlines

Oncolytics Biotech (TSE ONC) News Headlines

Source:
DateHeadline
BRIEF-Oncolytics Biotech Chief Medical Officer To Leave Effective April 23BRIEF-Oncolytics Biotech Chief Medical Officer To Leave Effective April 23
www.reuters.com - April 18 at 10:10 AM
Oncolytics Biotech(R) Announces Management ChangeOncolytics Biotech(R) Announces Management Change
finance.yahoo.com - April 17 at 4:10 PM
ONCYF: A Whirlwind 2017 Readies Spate of New TrialsONCYF: A Whirlwind 2017 Readies Spate of New Trials
finance.yahoo.com - March 26 at 10:42 AM
Oncolytics Biotech Inc. (ONC) to Post FY2018 Earnings of ($0.12) Per Share, Zacks Investment Research ForecastsOncolytics Biotech Inc. (ONC) to Post FY2018 Earnings of ($0.12) Per Share, Zacks Investment Research Forecasts
www.americanbankingnews.com - March 15 at 8:44 AM
BRIEF-Oncolytics Biotech Inc Announces 2017 Year-End ResultsBRIEF-Oncolytics Biotech Inc Announces 2017 Year-End Results
www.reuters.com - March 9 at 11:17 AM
M&A, Innovation & New Drugs to Drive Pharma StocksM&A, Innovation & New Drugs to Drive Pharma Stocks
www.zacks.com - March 8 at 4:36 PM
Merck Turns to Tumor-Killing Viruses to Boost Immune Cancer ... - BloombergMerck Turns to Tumor-Killing Viruses to Boost Immune Cancer ... - Bloomberg
www.bloomberg.com - March 2 at 4:28 PM
Oncolytics Biotech (ONC) Price Target Raised to C$3.25Oncolytics Biotech (ONC) Price Target Raised to C$3.25
www.americanbankingnews.com - February 26 at 2:40 PM
BRIEF-Oncolys BioPharma invests in US Biotech Venture Specialized in Development of Novel Oncolytic AdenovirusBRIEF-Oncolys BioPharma invests in US Biotech Venture Specialized in Development of Novel Oncolytic Adenovirus
www.reuters.com - February 16 at 4:04 PM
Oncolytics Biotech(R) to Present at the RBC Capital Markets 2018 Healthcare ConferenceOncolytics Biotech(R) to Present at the RBC Capital Markets 2018 Healthcare Conference
finance.yahoo.com - February 14 at 8:45 AM
Research Reports on Oncolytics Biotech, Aurinia Pharma, Immunovaccine, and IntelliPharmaCeuticsResearch Reports on Oncolytics Biotech, Aurinia Pharma, Immunovaccine, and IntelliPharmaCeutics
finance.yahoo.com - February 12 at 8:42 AM
Oncolytics Biotech(R) to Host Conference Call Outlining the Treatment Paradigm of Metastatic Breast Cancer Subtypes and Provide Topline Information on its Phase 3 Registration Study with REOLYSIN(R)Oncolytics Biotech(R) to Host Conference Call Outlining the Treatment Paradigm of Metastatic Breast Cancer Subtypes and Provide Topline Information on its Phase 3 Registration Study with REOLYSIN(R)
finance.yahoo.com - February 1 at 8:47 AM
Oncolytics Biotech® Inc. Announces Plans to Apply to List Common Shares on the NASDAQ Capital MarketOncolytics Biotech® Inc. Announces Plans to Apply to List Common Shares on the NASDAQ Capital Market
finance.yahoo.com - January 29 at 8:48 AM
Oncolytics Biotech(R) Named to the 2018 OTCQX Best 50Oncolytics Biotech(R) Named to the 2018 OTCQX Best 50
finance.yahoo.com - January 25 at 8:41 AM
BRIEF-Oncolytics Biotech Receives Final Advice Letter From European Medicines Agency For Reolysin In Metastatic Breast CancerBRIEF-Oncolytics Biotech Receives Final Advice Letter From European Medicines Agency For Reolysin In Metastatic Breast Cancer
www.reuters.com - December 5 at 11:55 AM
Oncolytics Biotech® Establishes Scientific Advisory Board Focused ... - PR Newswire (press release)Oncolytics Biotech® Establishes Scientific Advisory Board Focused ... - PR Newswire (press release)
www.prnewswire.com - November 30 at 10:50 AM
Oncolytics Biotech (ONCYF) Updates On Clinical Data & Development Plan - SlideshowOncolytics Biotech (ONCYF) Updates On Clinical Data & Development Plan - Slideshow
seekingalpha.com - November 21 at 9:00 AM
BRIEF-Oncolytics Biotech Inc reports qtrly share of $0.02BRIEF-Oncolytics Biotech Inc reports qtrly share of $0.02
www.reuters.com - November 9 at 10:06 AM
Oncolytics Biotech® Appoints Deborah Brown to Board of Directors - PR Newswire (press release)Oncolytics Biotech® Appoints Deborah Brown to Board of Directors - PR Newswire (press release)
www.prnewswire.com - November 4 at 8:31 AM
Sorrento Therapeutics: Buy, Sell Or Hold After Its Big Rally?Sorrento Therapeutics: Buy, Sell Or Hold After Its Big Rally?
seekingalpha.com - October 14 at 6:26 AM
Form 6-K ONCOLYTICS BIOTECH INC For: Oct 11 - StreetInsider.comForm 6-K ONCOLYTICS BIOTECH INC For: Oct 11 - StreetInsider.com
www.streetinsider.com - October 13 at 7:44 AM
Oncolytics’ (ONCYF) End of Phase II MeetingOncolytics’ (ONCYF) End of Phase II Meeting
finance.yahoo.com - September 22 at 7:21 AM
BRIEF-Oncolytics announces successful end-of-Phase 2 meeting with FDA for reolysinBRIEF-Oncolytics announces successful end-of-Phase 2 meeting with FDA for reolysin
www.reuters.com - September 19 at 6:11 AM
BRIEF-Oncolytics Biotech announces first patient treated in Muk Eleven studyBRIEF-Oncolytics Biotech announces first patient treated in Muk Eleven study
www.reuters.com - September 14 at 8:46 AM
Oncolytics Biotech® Announces the Presentation of REOLYSIN ... - PR Newswire (press release)Oncolytics Biotech® Announces the Presentation of REOLYSIN ... - PR Newswire (press release)
www.prnewswire.com - September 12 at 8:40 AM
Oncolytics’ (ONCYF) Second Quarter ResultsOncolytics’ (ONCYF) Second Quarter Results
finance.yahoo.com - August 15 at 5:44 AM
FY2017 EPS Estimates for Oncolytics Biotech Inc. (ONC) Decreased by AnalystFY2017 EPS Estimates for Oncolytics Biotech Inc. (ONC) Decreased by Analyst
www.americanbankingnews.com - August 10 at 10:42 AM
Oncolytics Biotech® Inc. Announces 2017 Second Quarter ResultsOncolytics Biotech® Inc. Announces 2017 Second Quarter Results
finance.yahoo.com - August 4 at 6:40 AM
Oncolytics reports 2Q lossOncolytics reports 2Q loss
finance.yahoo.com - August 4 at 6:40 AM
Oncolytics Biotech® Inc. to Present at the Canaccord Genuity 37th Annual Growth Conference - PR Newswire (press release)Oncolytics Biotech® Inc. to Present at the Canaccord Genuity 37th Annual Growth Conference - PR Newswire (press release)
www.prnewswire.com - August 2 at 6:37 AM
BRIEF-Oncolytics Biotech granted end-of-phase 2 meeting with FDABRIEF-Oncolytics Biotech granted end-of-phase 2 meeting with FDA
www.reuters.com - July 27 at 6:04 AM
Oncolytics Biotech® to Present REOLYSIN® Safety Data in combination with chemotherapy at ESMO 2017 CongressOncolytics Biotech® to Present REOLYSIN® Safety Data in combination with chemotherapy at ESMO 2017 Congress
finance.yahoo.com - July 27 at 6:04 AM
Oncolytics (ONCYF) Raises CAD$11 MillionOncolytics (ONCYF) Raises CAD$11 Million
finance.yahoo.com - July 6 at 7:41 AM
Oncolytics® Biotech Inc. Appoints Andrew de Guttadauro, President of Oncolytics Biotech (US) Inc. - PR Newswire (press release)Oncolytics® Biotech Inc. Appoints Andrew de Guttadauro, President of Oncolytics Biotech (US) Inc. - PR Newswire (press release)
www.prnewswire.com - July 1 at 6:22 AM
Oncolytics Biotech® Inc. Opens US Based Office in San Diego - PR Newswire (press release)Oncolytics Biotech® Inc. Opens US Based Office in San Diego - PR Newswire (press release)
www.prnewswire.com - June 29 at 12:36 AM
Oncolytics Biotech® Prices Public Offering of UnitsOncolytics Biotech® Prices Public Offering of Units
www.prnewswire.com - May 24 at 7:16 PM
Oncolytics Biotech Prices Public Offering of UnitsOncolytics Biotech Prices Public Offering of Units
www.marketwatch.com - May 24 at 7:16 PM
BRIEF-Oncolytics Biotech prices public offering of unitsBRIEF-Oncolytics Biotech prices public offering of units
www.reuters.com - May 24 at 7:15 PM
FDA Grants Fast Track Status to Oncolytics Reolysin for Breast CancerFDA Grants Fast Track Status to Oncolytics' Reolysin for Breast Cancer
www.baystreet.ca - May 8 at 12:09 PM
BRIEF-Oncolytics Biotech Inc announces FDA fast track designation for ReolysinBRIEF-Oncolytics Biotech Inc announces FDA fast track designation for Reolysin
www.reuters.com - May 8 at 12:09 PM
Oncolytics Biotech® Inc. Announces Voting Results from its Annual Meeting of Shareholders - PR Newswire (press release)Oncolytics Biotech® Inc. Announces Voting Results from its Annual Meeting of Shareholders - PR Newswire (press release)
www.prnewswire.com - May 5 at 7:20 PM
Oncolytics Biotech® Inc. Announces 2017 First Quarter ResultsOncolytics Biotech® Inc. Announces 2017 First Quarter Results
www.prnewswire.com - May 5 at 8:53 AM
Oncolytics reports 1Q lossOncolytics reports 1Q loss
marketbeat.com - May 5 at 7:18 AM
Oncolytics Biotech announces registration pathway and clinical development plan - Seeking AlphaOncolytics Biotech announces registration pathway and clinical development plan - Seeking Alpha
seekingalpha.com - April 14 at 6:40 PM
Biopharmaceutical Market Scope Rising With Escalating Health Concerns - IndustryARCBiopharmaceutical Market Scope Rising With Escalating Health Concerns - IndustryARC
globenewswire.com - March 28 at 6:48 PM
BRIEF-Shanghai Shyndec Pharmas unit fined by food and drug authorities - ReutersBRIEF-Shanghai Shyndec Pharma's unit fined by food and drug authorities - Reuters
www.reuters.com - March 4 at 12:03 AM
Global Oncolytic Virus Landscape 2017: Key Players, Key Technologies, Projects, Business Deals and Private and ... - GlobeNewswire (press release)Global Oncolytic Virus Landscape 2017: Key Players, Key Technologies, Projects, Business Deals and Private and ... - GlobeNewswire (press release)
globenewswire.com - January 31 at 5:48 AM
Oncolytics Biotech® Inc. Appoints Dr. Matt Coffey to the Role of President and CEO - PR Newswire (press release)Oncolytics Biotech® Inc. Appoints Dr. Matt Coffey to the Role of President and CEO - PR Newswire (press release)
www.prnewswire.com - January 21 at 7:40 AM
BRIEF-Oncolytics Biotech names Matt Coffey CEOBRIEF-Oncolytics Biotech names Matt Coffey CEO
www.reuters.com - January 19 at 11:41 PM
Targovax announces appointment of Erik Digman Wiklund as CFO ... - GlobeNewswire (press release)Targovax announces appointment of Erik Digman Wiklund as CFO ... - GlobeNewswire (press release)
globenewswire.com - January 5 at 5:53 AM

SEC Filings

Oncolytics Biotech (TSE:ONC) SEC Filings

This page is loading this company's SEC Filings. Please wait...

Social Media

Financials

Financials are not available for this stock.

Chart

Oncolytics Biotech (TSE ONC) Stock Chart for Sunday, April, 22, 2018

Loading chart…

This page was last updated on 4/22/2018 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.